DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-27

Last Posted Date: 2025-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 55

Registration Number: NCT02916771

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Endometrial Cancer

Interventions: Drug: Avelumab
Drug: Talazoparib
Drug: Axitinib

First Posted Date: 2016-09-23

Last Posted Date: 2024-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 106

Registration Number: NCT02912572

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Trial of CUDC-907 in Children and Young Adults with Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Neuroblastoma
Brain Tumor
Solid Tumor

Interventions: Drug: CUDC-907

First Posted Date: 2016-09-21

Last Posted Date: 2025-02-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT02909777

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
University of California, San Francisco, Benioff Children's Hospital, San Francisco, California, United States

and more 1 locations

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

Phase 2

Completed

Conditions: Smoldering Multiple Myeloma

Interventions: Drug: Nivolumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-09-16

Last Posted Date: 2023-06-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 8

Registration Number: NCT02903381

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Leuprolide
Drug: Prednisone
Drug: Abiraterone Acetate

First Posted Date: 2016-09-16

Last Posted Date: 2025-02-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 118

Registration Number: NCT02903368

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States

and more 1 locations

Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone

Phase 2

Active, not recruiting

Conditions: Bone Cancer

Interventions: Drug: Stereotactic Body Radiation Therapy (SBRT)
Device: Stereotactic Linear Accelerator

First Posted Date: 2016-08-26

Last Posted Date: 2024-08-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 150

Registration Number: NCT02880319

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer

Phase 2

Active, not recruiting

Conditions: Inflammatory Breast Cancer (IBC)

Interventions: Drug: Ruxolitinib
Drug: Paclitaxel
Drug: Doxorubicin
Drug: Cyclophosphamide

First Posted Date: 2016-08-23

Last Posted Date: 2025-03-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT02876302

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 1 locations

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: LY2606368

First Posted Date: 2016-08-22

Last Posted Date: 2022-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT02873975

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Drug: Nivolumab
Drug: Rucaparib

First Posted Date: 2016-08-22

Last Posted Date: 2025-05-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 73

Registration Number: NCT02873962

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Palbociclib With Everolimus + Exemestane In BC

Phase 1

Completed

Conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Hormone Receptor (HR)-Positive Breast Cancer

Interventions: Drug: Palbociclib
Drug: Everolimus
Drug: Exemestane

First Posted Date: 2016-08-18

Last Posted Date: 2022-08-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT02871791

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Home Terms & Conditions Privacy Policy